Cipla rallies nearly 3% on getting US patent for stemcell product – Economic Times
|
Cipla rallies nearly 3% on getting US patent for stemcell product
Economic Times NEW DELHI: Cipla Ltd rallied as much as 2.7 per cent in trade on Thursday, after Stempeutics Research received a process patent from the United States Patent and Trademarks Office for its novel stem cell-based drug Stempeucel, said media reports. Cipla's Stempeutics gets US patent for stemcell product Stempeutics Receives US Process Patent for Its Novel Stem Cell Drug … Stempeutics receives US process patent for novel stem cell drug Stempeucel |
